The designation was supported by data from the Phase 2b proof-of-concept trial of ribaxamase, which evaluated its efficacy to prevent the onset of primary CDI, antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial resistance (AMR) in hospitalized patients with lower respiratory infection receiving IV ceftriaxone. The study met its primary endpoint of significantly reducing CDI, with ribaxamase achieving a 71.4% relative risk reduction (P=0.045) in CDI rates vs. placebo. Treatment with ribaxamase also showed a significant reduction in new colonization by vancomycin-resistant enterococci (VRE) compared to placebo (P=0.0002). Additional data analysis, such as the ability of ribaxamase to prevent the emergence and proliferation of AMR in the gut microbiome, is ongoing.